[Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT)].
Identifieur interne : 002F11 ( PubMed/Corpus ); précédent : 002F10; suivant : 002F12[Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT)].
Auteurs : F. Bambini ; C A De Stefano ; L. Giannetti ; L. Memè ; M. PellecchiaSource :
- Minerva stomatologica [ 0026-4970 ] ; 2003.
English descriptors
- KwdEn :
- Adult, Alendronate (administration & dosage), Alendronate (pharmacology), Alendronate (therapeutic use), Bicuspid (surgery), Dental Implantation, Endosseous, Drug Evaluation, Female, Humans, Jaw, Edentulous, Partially (diagnostic imaging), Jaw, Edentulous, Partially (surgery), Molar (surgery), Osseointegration (drug effects), Tomography, Emission-Computed, Single-Photon, Wound Healing.
- MESH :
- chemical , administration & dosage : Alendronate.
- chemical , pharmacology : Alendronate.
- chemical , therapeutic use : Alendronate.
- diagnostic imaging : Jaw, Edentulous, Partially.
- drug effects : Osseointegration.
- surgery : Bicuspid, Jaw, Edentulous, Partially, Molar.
- Adult, Dental Implantation, Endosseous, Drug Evaluation, Female, Humans, Tomography, Emission-Computed, Single-Photon, Wound Healing.
Abstract
Biphosphonates are a large class of drugs which inhibits the resorbing activity of osteoclasts. The aim of this study was to evaluate the influence of topical application of the biphosphonate alendronate on the integration process of endosseus implants placed in a partially edentulous patient. After incision and elevation of a mucoperiosteal flap and carrying out the osteotomy, 2 SLA implants 10 mm long and 3.5 mm wide were inserted in the area of # 4.5 and 4.6. Before placement of # 4.5, a paste made of grinded tablets of alendronate and Rifocin was applied in the osteotomy. Fifteen days after stage I, an evaluation of the osteoblastic peri-implant activity was carried out using single photon emission computerized tomography. Healing was within normal limits. Four months after stage I, the 2 implants were uncovered and considered clinically and radiographically integrated. The osteoblastic activity was judged similar bet-ween the 2 implants in terms of quality of biological response. Osseous scintigraphy and the achievement of implant osseointegration demonstrate the lack of toxicity of the topical application of the biphosphonate alendronate during the initial osseous healing. However, new experimental studies and clinical trials are necessary to confirm the results obtained.
PubMed: 12874537
Links to Exploration step
pubmed:12874537Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT)].</title><author><name sortKey="Bambini, F" sort="Bambini, F" uniqKey="Bambini F" first="F" last="Bambini">F. Bambini</name><affiliation><nlm:affiliation>Cattedra di Chirurgia Speciale, Odontostomatologica, Istituto di Scienze Odontostomatologiche, Università degli Studi di Ancona, Ancona, Italy. m.pallecchia@libero.it</nlm:affiliation></affiliation></author><author><name sortKey="De Stefano, C A" sort="De Stefano, C A" uniqKey="De Stefano C" first="C A" last="De Stefano">C A De Stefano</name></author><author><name sortKey="Giannetti, L" sort="Giannetti, L" uniqKey="Giannetti L" first="L" last="Giannetti">L. Giannetti</name></author><author><name sortKey="Meme, L" sort="Meme, L" uniqKey="Meme L" first="L" last="Memè">L. Memè</name></author><author><name sortKey="Pellecchia, M" sort="Pellecchia, M" uniqKey="Pellecchia M" first="M" last="Pellecchia">M. Pellecchia</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12874537</idno><idno type="pmid">12874537</idno><idno type="wicri:Area/PubMed/Corpus">002F11</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT)].</title><author><name sortKey="Bambini, F" sort="Bambini, F" uniqKey="Bambini F" first="F" last="Bambini">F. Bambini</name><affiliation><nlm:affiliation>Cattedra di Chirurgia Speciale, Odontostomatologica, Istituto di Scienze Odontostomatologiche, Università degli Studi di Ancona, Ancona, Italy. m.pallecchia@libero.it</nlm:affiliation></affiliation></author><author><name sortKey="De Stefano, C A" sort="De Stefano, C A" uniqKey="De Stefano C" first="C A" last="De Stefano">C A De Stefano</name></author><author><name sortKey="Giannetti, L" sort="Giannetti, L" uniqKey="Giannetti L" first="L" last="Giannetti">L. Giannetti</name></author><author><name sortKey="Meme, L" sort="Meme, L" uniqKey="Meme L" first="L" last="Memè">L. Memè</name></author><author><name sortKey="Pellecchia, M" sort="Pellecchia, M" uniqKey="Pellecchia M" first="M" last="Pellecchia">M. Pellecchia</name></author></analytic><series><title level="j">Minerva stomatologica</title><idno type="ISSN">0026-4970</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Alendronate (administration & dosage)</term><term>Alendronate (pharmacology)</term><term>Alendronate (therapeutic use)</term><term>Bicuspid (surgery)</term><term>Dental Implantation, Endosseous</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Jaw, Edentulous, Partially (diagnostic imaging)</term><term>Jaw, Edentulous, Partially (surgery)</term><term>Molar (surgery)</term><term>Osseointegration (drug effects)</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Wound Healing</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Alendronate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Alendronate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Alendronate</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Jaw, Edentulous, Partially</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Osseointegration</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Bicuspid</term><term>Jaw, Edentulous, Partially</term><term>Molar</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dental Implantation, Endosseous</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Wound Healing</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Biphosphonates are a large class of drugs which inhibits the resorbing activity of osteoclasts. The aim of this study was to evaluate the influence of topical application of the biphosphonate alendronate on the integration process of endosseus implants placed in a partially edentulous patient. After incision and elevation of a mucoperiosteal flap and carrying out the osteotomy, 2 SLA implants 10 mm long and 3.5 mm wide were inserted in the area of # 4.5 and 4.6. Before placement of # 4.5, a paste made of grinded tablets of alendronate and Rifocin was applied in the osteotomy. Fifteen days after stage I, an evaluation of the osteoblastic peri-implant activity was carried out using single photon emission computerized tomography. Healing was within normal limits. Four months after stage I, the 2 implants were uncovered and considered clinically and radiographically integrated. The osteoblastic activity was judged similar bet-ween the 2 implants in terms of quality of biological response. Osseous scintigraphy and the achievement of implant osseointegration demonstrate the lack of toxicity of the topical application of the biphosphonate alendronate during the initial osseous healing. However, new experimental studies and clinical trials are necessary to confirm the results obtained.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12874537</PMID><DateCompleted><Year>2003</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0026-4970</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>6</Issue><PubDate><Year>2003</Year><Month>06</Month></PubDate></JournalIssue><Title>Minerva stomatologica</Title><ISOAbbreviation>Minerva Stomatol</ISOAbbreviation></Journal><ArticleTitle>[Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT)].</ArticleTitle><Pagination><MedlinePgn>331-8</MedlinePgn></Pagination><Abstract><AbstractText>Biphosphonates are a large class of drugs which inhibits the resorbing activity of osteoclasts. The aim of this study was to evaluate the influence of topical application of the biphosphonate alendronate on the integration process of endosseus implants placed in a partially edentulous patient. After incision and elevation of a mucoperiosteal flap and carrying out the osteotomy, 2 SLA implants 10 mm long and 3.5 mm wide were inserted in the area of # 4.5 and 4.6. Before placement of # 4.5, a paste made of grinded tablets of alendronate and Rifocin was applied in the osteotomy. Fifteen days after stage I, an evaluation of the osteoblastic peri-implant activity was carried out using single photon emission computerized tomography. Healing was within normal limits. Four months after stage I, the 2 implants were uncovered and considered clinically and radiographically integrated. The osteoblastic activity was judged similar bet-ween the 2 implants in terms of quality of biological response. Osseous scintigraphy and the achievement of implant osseointegration demonstrate the lack of toxicity of the topical application of the biphosphonate alendronate during the initial osseous healing. However, new experimental studies and clinical trials are necessary to confirm the results obtained.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bambini</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cattedra di Chirurgia Speciale, Odontostomatologica, Istituto di Scienze Odontostomatologiche, Università degli Studi di Ancona, Ancona, Italy. m.pallecchia@libero.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Stefano</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Giannetti</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Memè</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Pellecchia</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>ita</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Valutazione scintigrafica con metodica SPECT dell'effetto dei bifosfonati sul processo di osseointegrazione implantare.</VernacularTitle></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Stomatol</MedlineTA><NlmUniqueID>0421071</NlmUniqueID><ISSNLinking>0026-4970</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>X1J18R4W8P</RegistryNumber><NameOfSubstance UI="D019386">Alendronate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>D</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019386" MajorTopicYN="N">Alendronate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001641" MajorTopicYN="N">Bicuspid</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003758" MajorTopicYN="Y">Dental Implantation, Endosseous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="N">Drug Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007576" MajorTopicYN="N">Jaw, Edentulous, Partially</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008963" MajorTopicYN="N">Molar</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016348" MajorTopicYN="N">Osseointegration</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12874537</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002F11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:12874537
|texte= [Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT)].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:12874537" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a EdenteV2
| This area was generated with Dilib version V0.6.32. |  |